Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1982 4
1983 1
1984 4
1985 2
1986 1
1987 1
1988 1
1989 2
1990 1
1992 1
1995 3
1996 1
1997 1
1999 2
2000 1
2001 3
2002 1
2004 2
2005 5
2006 3
2007 5
2008 3
2009 5
2010 5
2011 4
2012 6
2013 2
2014 3
2015 2
2016 1
2017 2
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F. Knödler M, et al. Among authors: lindhofer h. Br J Cancer. 2018 Aug;119(3):296-302. doi: 10.1038/s41416-018-0150-6. Epub 2018 Jul 10. Br J Cancer. 2018. PMID: 29988111 Free PMC article. Clinical Trial.
Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.
Hess J, Ruf P, Lindhofer H. Hess J, et al. Among authors: lindhofer h. Future Oncol. 2012 Jan;8(1):73-85. doi: 10.2217/fon.11.138. Future Oncol. 2012. PMID: 22149036 Review.
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D, Lindhofer H, Bokemeyer C. Seimetz D, et al. Among authors: lindhofer h. Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27. Cancer Treat Rev. 2010. PMID: 20347527 Review.
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.
Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. Chaudry MA, et al. Among authors: lindhofer h. Br J Cancer. 2007 Apr 10;96(7):1013-9. doi: 10.1038/sj.bjc.6603505. Epub 2007 Feb 27. Br J Cancer. 2007. PMID: 17325709 Free PMC article. Review.
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Deppisch N, Ruf P, Eißler N, Lindhofer H, Mocikat R. Deppisch N, et al. Among authors: lindhofer h. Oncotarget. 2017 Jan 17;8(3):4520-4529. doi: 10.18632/oncotarget.13888. Oncotarget. 2017. PMID: 27966460 Free PMC article.
Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.
Kieslich A, Ruf P, Lindhofer H, Buhmann R, Eggert A, Hundsdoerfer P. Kieslich A, et al. Among authors: lindhofer h. Leuk Lymphoma. 2017 Aug;58(8):1989-1992. doi: 10.1080/10428194.2016.1272687. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28093004 No abstract available.
Structural and functional characterization of the trifunctional antibody catumaxomab.
Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. Chelius D, et al. Among authors: lindhofer h. MAbs. 2010 May-Jun;2(3):309-19. doi: 10.4161/mabs.2.3.11791. Epub 2010 May 16. MAbs. 2010. PMID: 20418662 Free PMC article.
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
Haense N, Atmaca A, Pauligk C, Steinmetz K, Marmé F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE. Haense N, et al. Among authors: lindhofer h. BMC Cancer. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0. BMC Cancer. 2016. PMID: 27387446 Free PMC article.
Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Eissler N, et al. Among authors: lindhofer h. Cancer Res. 2012 Aug 15;72(16):3958-66. doi: 10.1158/0008-5472.CAN-12-0146. Epub 2012 Jun 28. Cancer Res. 2012. PMID: 22745368 Free article.
Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
Eissler N, Mysliwietz J, Deppisch N, Ruf P, Lindhofer H, Mocikat R. Eissler N, et al. Among authors: lindhofer h. Mol Med. 2013 Apr 30;19(1):54-61. doi: 10.2119/molmed.2012.00140. Mol Med. 2013. PMID: 23552725 Free PMC article.
75 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page